Please ensure Javascript is enabled for purposes of website accessibility

3 Out-of-Favor Investments to Buy Today

By Todd Wenning - Updated Apr 6, 2017 at 1:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Understanding the market's ebb and flow is the key to success.

The Taoist concept of wu wei is about natural action -- knowing when to act and when not to act. It can also teach us a lot about investing.

Literally "non-doing," the principle of wu wei is found in the martial arts disciplines of aikido and judo, where the goal is to use an attacker's force to the defender's advantage. The ancient Chinese military strategist Sun Tzu preached this discipline in The Art of War, advising men "to avoid what is strong and to strike at what is weak."  

While we might not be engaging in hand-to-hand combat in investing, we should learn how to use the market's emotions to our advantage. Warren Buffett's famous quote, "Be fearful when others are greedy and be greedy only when others are fearful," whether intentional or not, is quite Taoist in principle. In essence, the Oracle of Omaha is saying that the key to long-term investing success is to avoid what is temporarily strong and buy what is temporarily weak.   

Wax on, wax off
To illustrate, let's hop in our Delorean and set the flux capacitor to June 2000. The Los Angeles Lakers had just won the NBA championship, boy bands ruled the airwaves, and "new economy" technology stocks were all the rage. Meanwhile, industries like energy, railroads, and machinery were largely ignored and written off as antiquated.

Looking back, it seems obvious what investors should have done -- the Nasdaq is still down more than 50% since then, while the Vanguard Energy Index (VGENX) fund has nearly doubled -- but in 2000, the choice wasn't so simple. At the time, crude oil was just $27 a barrel, and with other commodities also under pressure, demand for industrial products and services was quite low.

These gloomy fundamentals, in contrast with the allure of promising new technology, made it psychologically easier for investors to buy, say, over Caterpillar. It may have been the easy choice, but it wasn't the right choice. Again, buying what was temporarily weak would have been the better investment in the long run even though it was the harder decision to make.

Today, there are once again a number of sectors that have fallen out of favor and present strong buying opportunities for the patient investor. In fact, two of our favorite sectors at Motley Fool Pro are health care and financials. It's true that there could be some trouble spots within those sectors, but there are also strong companies that have been thrown out with the proverbial bath water and deserve a closer look.

Health-care values abound
In the health-care sector, for instance, we bought the medical equipment maker Kinetic Concepts (NYSE: KCI) in late 2008 at a time when the market was overly concerned with the debt the company took on to acquire LifeCell and patent challenges to its highly-profitable VAC Therapy wound-care system.

To the first concern, we noted that the chief financial officer had experience successfully paying down debt once before and that Kinetic Concepts generated more than enough free cash flow to deleverage once again. Second, we learned just how valuable and widely used the VAC Therapy brand was in the medical industry, and given that doctors and nurses tend to stick with what they know works for their patients, we weren't as concerned as the market was regarding competition threats.

Since then, Kinetic Concepts has won a number of patent judgments and our investment is up 76% versus 22% for the market over the same period.  We still consider it a "buy" today.

At Pro, we see similar value in GlaxoSmithKline (NYSE: GSK) today. Glaxo shares have fallen roughly 10% since mid-April, largely because of concerns about Europe and the weakening British pound, which effectively diminishes the value of dollar-denominated profits for American investors.

Still, Glaxo has a robust research and development pipeline with a good balance between late-stage FDA trials and early-stage human clinical trials, is rapidly expanding its emerging market operations, and is led by an energetic and innovative CEO in Andrew Witty, who we think has Glaxo pointed in a good direction. Plus, Glaxo's 5.4% dividend yield provides a real return while you wait for the stock to turn around.

Financials -- yes, financials
As far as financials go, we prefer smaller regional banks and non-bank financials like conservatively-run insurers and brokerage firms.

In March, for example, we bought shares of the SPDR KBW Regional Banking (NYSE: KRE) exchange-traded fund, which holds roughly 50 small regional banks spread out across the United States. It's true that these regional banks have significant exposure to commercial real estate, but we dissected each of the underlying holdings of the ETF and found them to be, on the whole, sufficiently capitalized to absorb possible losses.

To illustrate, a number of the ETF's underlying holdings, including Bank of Hawaii (NYSE: BOH), Valley National, and IberiaBank (Nasdaq: IBKC), were strong enough to maintain their dividend payouts through the credit crisis. Other holdings, like Hudson City Bancorp (Nasdaq: HCBK) and People's United Bank (Nasdaq: PBCT) didn't need to take TARP funds.

Surfing the waves
Buffett may not have studied the Tao Te Ching, but avoiding what is hot right now and buying what's not is at the heart of value investing. If done properly with patience and discipline over time, you can greatly improve both your investing accuracy and your returns.

At our Motley Fool Pro service, we have a stated goal of profitably closing at least 75% of our positions, which forces us to focus on the price we're paying for our investments. Buying out-of-favor yet strong investments at good prices greatly reduces our risk of overpaying and realizing permanent losses. Kinetic Concepts, GlaxoSmithKline, and SPDR KBW Regional Banking ETF are just three investments that fit this bill today.

Since we launched Pro in the fall of 2008, we've stayed well above our 75% accuracy goal and complement our stock and ETF investments with options strategies to generate additional income. If you'd like to learn more about our strategies at Pro -- as well as get a free report with five strategies for growing your wealth in a volatile, range-bound market, simply enter your email address in the box below.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
$44.05 (-0.82%) $0.36
Bank of Hawaii Corporation Stock Quote
Bank of Hawaii Corporation
$78.16 (-0.47%) $0.36
People's United Financial, Inc. Stock Quote
People's United Financial, Inc.
Acelity L.P. Inc. Stock Quote
Acelity L.P. Inc.
SPDR Series Trust - SPDR S&P Regional Banking ETF Stock Quote
SPDR Series Trust - SPDR S&P Regional Banking ETF
$63.64 (0.52%) $0.33
IBERIABANK Corporation Stock Quote
IBERIABANK Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.